EPS of 5c beat estimates of 4.8c; revenue of $213.2M beat estimates by 4%. EBITDA of $30.75M beat estimates by 2%. Revenue was a record, up 48%. Canadian operations (clinics and platforms) performed very well. Guidance of sales of $950M+ and EBITDA of $125M+ were both above current estimates. Organic growth was a solid 15%. WELL also announced some cost-cutting measures to be implemented. The stock is down, but we can't really explain why. It was a good quarter, with good growth and a good outlook. Here are some other comments below: WELL Health Technologies' 4Q results continued its streak of beating consensus forecasts for over four years, "aided by strong performances in its Canadian business where Adjusted EBITDA increased 39% y/y in F2023." TD analyst David Kwan says that as well as the strong results, the new revenue guidance for the year which raises targets by 6% to 8% "implies acceleration in growth," compared with 2023. "We believe this strong result should help support a continued rebound in its share price".
5i Research Answer: